About Us
BIOIO was founded based on two decades of research to understand better how drugs work. In particular, we leverage our learnings on how the widely used medicines, such as rapamycin, metformin, bisphosphonates, and antidepressants, work. This led us to define a gold standard for drug MoA elucidation, leading to our genetics-based MOAT platform. Increasingly, our process has become big data driven and automated. We propose this is key to accelerating drug development. Our team has evolved to add in in silico technology to virtualize our wet-lab.
Meet Our Team
Dr. Peterson trained @ MIT and Harvard in two HHMI labs. Assistant Professor at Washington University School of Medicine (WashU).
Trained @ Netherlands Cancer Institute (NKI). Previously BD at the longevity company Rejuveron Life Sciences and biologics manufacturer Batavia Biosciences.
BIOIO-2001 lead.
Associate Professor @ WashU. 7 INDs. Director of WashU’s Center for Drug Discovery.
Professor of Medicine UT Southwestern. GLP-1RA pioneering clinical trialist.
BIOIO-1xx1 lead.
Inventor of BIOIO-1001, 10+ years experience in this chemical class. Ex-Pfizer and Pfizer acquired companies.
Cumulus Oncology, Former Exec VP and CSO of Fresenius group.
Assistant Professor @ Yale. Co-founder Meliora Therapeutics. MoA Analysis.
Associate Professor @ Duke University. Co-founder Tavros Therapeutics. Pre-clinical oncology collaborator.
CSO, Aclaris Therapeutics. Previously, Pfizer Executive Director R&D. St. Louis company building advice.
Professor, Chair of Endocrinology @ WashU. Lipid metabolism expertise.
